Pharmaceutical

Holoclara gains Series A financing for worm-derived therapies

Holoclara has secured $16m in a Series A financing to advance new worm-derived therapies targeting allergic and autoimmune diseases.

Jun 30, 2024 - 04:00
Holoclara gains Series A financing for worm-derived therapies
Holoclara has secured $16m in a Series A financing to advance new worm-derived therapies targeting allergic and autoimmune diseases.
Read the original article

Tags:

Previous Article

Alumis raises $250m in IPO as biotech stock stirs

Next Article

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pharmaceutical Compliance Management Software for the Pharmaceutical Industry

Pharmaceutical Compliance Management Software for the P...

Sep 24, 2024

STAT+: Abortion policy in the spotlight, DeSantis’ importation showdown, and new price hike analysis

STAT+: Abortion policy in the spotlight, DeSantis’ impo...

Aug 27, 2023

FDA grants clearance to Gilead Sciences’ sNDA for Veklury

FDA grants clearance to Gilead Sciences’ sNDA for Veklury

Aug 26, 2023